AUG 18, 2026 · PHASE 2 TRIAL
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
ClinicalTrials.gov
Phase 2 registry record with completed enrollment but no results posted; cannot assess efficacy or safety from registration alone.
Reported
PhasePHASE 2
Sample size (actual enrollment)55
Primary outcome measureObjective response rate (ORR) by RECIST 1.1…